LEADER 01053nam0 22002771i 450 001 UON00489625 005 20231205105326.519 010 $a01-568-0676-2 100 $a20180629f1962 |0itac50 ba 101 $aeng 102 $aUS 105 $a|||| 1|||| 200 1 $a73 poems$fby E. E. Cummings 210 $aNew York$cHarcourt Brace Jovanovich$dc1962 215 $a1 v.$d18 cm. 410 1$1001UON00489627$12001 $aHarbrace Paperbound Library$1210 $aNew York$cHarcourt Brace Jovanovich$v52 620 $aUS$dNew York$3UONL000050 676 $a811.52$cPoesia americana. 1900-1945$v21 700 1$aCUMMINGS$bEdward Estlin$3UONV187592$0196329 712 $aHarcourt Brace Jovanovich$3UONV249883$4650 801 $aIT$bSOL$c20240220$gRICA 899 $aSIBA - SISTEMA BIBLIOTECARIO DI ATENEO$2UONSI 912 $aUON00489625 950 $aSIBA - SISTEMA BIBLIOTECARIO DI ATENEO$dSI NordA V A 0166 $eSI SNA285 7 0166 996 $a73 Poems$9524254 997 $aUNIOR LEADER 02035nam 2200457z- 450 001 9910557565503321 005 20211118 035 $a(CKB)5400000000043972 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/74376 035 $a(oapen)doab74376 035 $a(EXLCZ)995400000000043972 100 $a20202111d2020 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aEvidence-based Advance and Management of Adverse Events of Immunotherapy for Cancer 210 $cFrontiers Media SA$d2020 215 $a1 online resource (207 p.) 311 08$a2-88966-247-0 330 $aThis eBook is a collection of articles from a Frontiers Research Topic. Frontiers Research Topics are very popular trademarks of the Frontiers Journals Series: they are collections of at least ten articles, all centered on a particular subject. With their unique mix of varied contributions from Original Research to Review Articles, Frontiers Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author by contacting the Frontiers Editorial Office: frontiersin.org/about/contact 606 $aPharmacology$2bicssc 606 $aScience: general issues$2bicssc 610 $aadverse event 610 $acancer 610 $aEvidence-based 610 $aimmunotherapy 610 $amanagement 615 7$aPharmacology 615 7$aScience: general issues 700 $aZhang$b Yonggang$4edt$01330023 702 $aMa$b Xuelei$4edt 702 $aZhou$b Shuang$4edt 702 $aZhang$b Yonggang$4oth 702 $aMa$b Xuelei$4oth 702 $aZhou$b Shuang$4oth 906 $aBOOK 912 $a9910557565503321 996 $aEvidence-based Advance and Management of Adverse Events of Immunotherapy for Cancer$93039698 997 $aUNINA LEADER 02314nam 2200457z- 450 001 9910136792003321 005 20210211 035 $a(CKB)3710000000631061 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/55432 035 $a(oapen)doab55432 035 $a(EXLCZ)993710000000631061 100 $a20202102d2015 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aThe Origin of the Plasma Cell Heterogeneity 210 $cFrontiers Media SA$d2015 215 $a1 online resource (80 p.) 225 1 $aFrontiers Research Topics 311 08$a9782889197347 311 08$a2889197344 330 $aPlasma cells (PCs) are terminally differentiated B-cells producing large amounts of immunoglobulins (Ig). In humans, most of circulating Ig are produced by bone marrow plasma cells. PCs differentiate from activated nai?ve or memory B-cells usually activated by specific antigens. It is still controversial whether the regulation of PCs numbers and the "active" in vivo Ig diversity depend or not on non-specific reactivation of B-cells during infections. Depending on the stimulus (T-independent/T-dependent antigen, cytokines, partner cells) and B-cell types (nai?ve or memory, circulating or germinal center, lymph nodes or spleen, B1 or B2...), both the phenotype and isotype of PCs differ suggesting that PC diversity is either linked to B-cell diversity or to the type of stimulus or to both. Knowledge of the mechanisms supporting PC diversity has important consequences for the management of i) plasma cell neoplasia such as Multiple Myeloma and Waldenstro?m's Macroglobulinemia, ii) vaccine protection against pathogens and iii) auto-immune diseases. 606 $aMedicine$2bicssc 610 $aAutoimmunity 610 $aAutophagy 610 $aB-cell 610 $aB1 610 $aCell Cycle 610 $adifferentiation 610 $aIL21 610 $aMyeloma 610 $aPlasma cell 615 7$aMedicine 700 $aDefrance$b Thierry$4auth$01837976 702 $aPellat-Deceunynck$b Catherine$4auth 906 $aBOOK 912 $a9910136792003321 996 $aThe Origin of the Plasma Cell Heterogeneity$94416852 997 $aUNINA